ArticleFrontiers in oncology2022
Association of metabolic syndrome and the risk of bladder cancer: A prospective cohort study.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Metabolic syndrome and bladder cancer risk: a comprehensive evidence synthesis combining bibliometric and meta-analysis approaches.BMC urology · 2025Pooled it
- Burden of bladder cancer in China from 1990 to 2023: temporal trends, modifiable risk factors, and implications for prevention.International journal of clinical oncology · 2026Article
- The Insulin-Urothelial Axis: Evaluating Insulin Resistance as a Convergent Driver of Bladder Cancer Across Diverse Risk Factor Profiles.International journal of molecular sciences · 2026Review
- Unraveling the connection between obesity, metabolic syndrome and osteoarthritis risk: a large-observational study.Diabetology & metabolic syndrome · 2025Article
- Diseases burden and trends of bladder cancer attributable to behavioral and metabolic factors among global and Chinese population, 1990-2021: results from the global burden of disease study 2021.Journal of health, population, and nutrition · 2025Article
- Metabolic Risk Factors at the Time of Cancer Diagnosis in Primary Care: A Cross-Sectional Study.Cureus · 2025Article
- Global Burden of Major Urologic Diseases in Women, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021.International journal of women's health · 2025Article
- Cholesterol Metabolism and Urinary System Tumors.Biomedicines · 2024Review
- Higher genetically predicted triglyceride level increases the bladder cancer risk independent of LDL and HDL levels.Scientific reports · 2024Article
- Metabolic syndrome increases osteoarthritis risk: findings from the UK Biobank prospective cohort study.BMC public health · 2024Article
- Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis.Frontiers in oncology · 2024Article
- The causal relationship between osteoarthritis and bladder cancer: A Mendelian randomization study.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Background: Metabolic syndrome (MetS) and its components have been shown as risk factors for several solid cancers. However, current epidemiological evidence about the relevance of MetS and bladder cancer risk was limited. Methods: We conducted a prospective cohort study of 476,986 participants with undiagnosed bladder cancer based on the UK Biobank. MetS was defined as the presence of at least three of the five selected indicators: hypertension, central obesity, raised triglyceride, reduced HDL-cholesterol, and raised fasting plasma glucose. Bladder cancer has been identified through contact with the British Cancer Registry (median follow-up time: 6.6 years). We assessed hazard ratio (HR) and 95% confidence interval (CI) through Cox proportional hazard regression after adjusting for demographic and lifestyle factors. Non-linear associations for individual MetS components were assessed by the restricted cubic spline method. Results: During a follow-up of 3,112,566 person-years, 487 cases of bladder cancer were ascertained. MetS (HR = 1.32, 95% CI = 1.08-1.61), central obesity (HR = 1.39, 95% CI = 1.15-1.68), dyslipidemia for HDL cholesterol (HR = 1.31, 95% CI = 1.04-1.66), and hyperglycemia (HR = 1.44, 95% CI = 1.16-1.79) were associated with elevated risk of bladder cancer. Bladder cancer risk increased with the number of MetS components. In stratified analyses, MetS showed similar effects in bladder cancer independently with sex, age, cigarette and alcohol use, physical activity, and dietary factors. Higher waist circumference, BMI, fasting blood glucose, and glycosylated hemoglobin were independently associated with increased risk of bladder cancer, with no evidence against non-linearity. Conclusion: MetS might be an independent risk factor for bladder cancer. Our findings highlighted the importance of individualized management of MetS components for preventing bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.